Back to Search Start Over

How to treat classical Hodgkin's lymphoma in older patients : Belgian expert opinion

Authors :
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'hématologie
Snauwaert, S
Van Hende, V
Janssens, A
André, Marc
Van Hecke, S
Van Den Neste, E
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'hématologie
Snauwaert, S
Van Hende, V
Janssens, A
André, Marc
Van Hecke, S
Van Den Neste, E
Source :
Belgian Journal of Hematology, Vol. 12, no.7, p. 296-304 (2021)
Publication Year :
2021

Abstract

Classical Hodgkin's lymphoma (cHL) is a rather rare disease with an incidence of 2-3/100,000 per year and typically presents in patients at the age of 20-30. lt is however well known that a second peak occurs at the age of 60-65 years.1 Nowadays Hodgkin is a curable disease for most of the younger patients but treatment is more difficult and less successful in the aider patient population. ln this review, we want to summarise the possibilities for the treatment of cHL patients above 60 years, with a focus on evidence from the raher rarely available clinical trials. We also look at future treatments . ln this article we will use the term 'aider.patients' for patients of 60 years and older at diagnosis. We will make a distinction between fit patients older than 60 years and frail or vulnerable patients (so called elderly).

Details

Database :
OAIster
Journal :
Belgian Journal of Hematology, Vol. 12, no.7, p. 296-304 (2021)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1328227745
Document Type :
Electronic Resource